1. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma;Mateos;N Engl J Med,2013
2. Curative strategy for high-risk smoldering myeloma (GEM-CESAR): carfilzomib, lenalidomide, and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with KRd, and maintenance with Rd;Mateos;Blood,2017
3. Daratumumab monotherapy for patients with intermediate or high-risk smoldering multiple myeloma (SMM): Centaurus, a randomized, open-label, multicenter phase 2 study;Hofmeister;Blood,2017
4. Autologous stem cell transplantation versus bortezomib-melphalan-prednisone for newly diagnosed multiple myeloma: second interim analysis of the phase 3 EMN02/HO95 study;Cavo;Blood,2017
5. Double autologous stem cell transplantation significantly prolongs progression-free survival and overall survival in comparison with single autotransplantation in newly diagnosed multiple myeloma: an analysis of phase 3 EMN02/HO95 study;Cavo;Blood,2017